Literature DB >> 8578579

Hepatocellular carcinoma cases with five-year survival and prognostic factors affecting the survival time.

H Onodera1, K Ukai, Y Minami.   

Abstract

Between 1980 and 1994, 178 patients were confirmed to have hepatocellular carcinoma (HCC) in our hospital. The 5-year survival rates in patients with HCC of stage I, II and IVA were 38.1%, 31.8% and 3.9%, respectively. No patient in stage III or IVB survived for more than four years. The 5-year survival rates of the patients treated by hepatic resection, ultrasonically guided percutaneous ethanol injection and transcatheter hepatic arterial embolization were 53.7%, 38.7% and 13.5%, respectively. The logrank test showed a significant difference in cumulative survival rates obtained in patients with HCC according to the tumor stage (p < 0.001) or principal treatment procedure (p < 0.001). Twelve patients survived for more than five years. We employed a Cox's proportional hazards model to estimate the factors significantly affecting the survival time. Variables with statistical significance were the clinical stage (p < 0.001), tumor size (maximal tumor diameter) (p < 0.001) and patient's age (p < 0.05). Conclusively, patients in the early stage of HCC associated with mild liver cirrhosis have a significantly better chance for long survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578579     DOI: 10.1620/tjem.176.203

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  2 in total

1.  Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Authors:  Tianlu Chen; Guoxiang Xie; Xiaoying Wang; Jia Fan; Yunping Qiu; Xiaojiao Zheng; Xin Qi; Yu Cao; Mingming Su; Xiaoyan Wang; Lisa X Xu; Yun Yen; Ping Liu; Wei Jia
Journal:  Mol Cell Proteomics       Date:  2011-04-25       Impact factor: 5.911

2.  LC/MS-Based Global Metabolomic Identification of Serum Biomarkers Differentiating Hepatocellular Carcinoma from Chronic Hepatitis B and Liver Cirrhosis.

Authors:  Hong Y Pan; Qing Q Wu; Qiao Q Yin; Yi N Dai; Yi C Huang; Wei Zheng; Tian C Hui; Mei J Chen; Ming S Wang; Jia J Zhang; Hai J Huang; Yong X Tong
Journal:  ACS Omega       Date:  2021-01-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.